Overview

Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers

Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetics of HL-TOF tab. 5 mg compared with those of XelJanz tab. in healthy volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Treatments:
Tofacitinib